Variables influencing anti-human immunodeficiency virus type 1 neutralizing human monoclonal antibody (NhMAb) production among infected Thais

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 44, Issue 5, 2013, Pages 825-841

  Akapirat, Siriwat ^a,b   Avihingsanon, Anchalee ^c,d   Ananworanich, Jintanat ^c,d   Schuetz, Alexandra ^b   Ramasoota, Pongrama ^a,e   Luplertlop, Natthanej ^a   Ono, Ken Ichiro ^f   Ikuta, Kazuyoshi ^g   Utachee, Piraporn ^h   Kameoka, Masanori ^g,h,i   Leaungwutiwong, Pornsawan ^a,e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Medical & Biological Laboratories Co Ltd   (Japan)

^g OSAKA UNIVERSITY   (Japan)

^h Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

ⁱ KOBE UNIVERSITY   (Japan)

Author keywords

CD4; CRF01_AE; HIV 1; Hybridoma; Neutralizing human monoclonal antibody

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDOMA; IMMUNOLOGY; VIRUS LOAD;

ADULT; ANTIBODIES, NEUTRALIZING; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; HYBRIDOMAS; VIRAL LOAD;

EID: 84893628395     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Aasa-Chapman M, Hayman A, Newton P, et al. Development of the antibody response in acute HIV-1 infection. AIDS 2004; 18: 371-81.
2. Arroyo M, Phanuphak N, Krasaesub S, et al. HIV type 1 molecular epidemiology among high-risk clients attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. AIDS Res Hum Retroviruses 2010; 26: 5-12.
3. Buchacher A, Predl R, Strutzenberger K, et al. Generation of human monoclonal antibo-dies against HIV-1 proteins; electrofusion and epstein-barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994; 10: 359-69.
4. Burton D, Barbas C, Persson M, Koenig S, Chanock R, Lerner R. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991; 88: 10134-7.
5. Burton D, Desrosiers R, Doms R, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5: 233-6.
6. Burton D, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266: 1024-7.
7. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
8. Cheingsong-Popov R, Lister S, Callow D, Kaleebu P, Beddows S, Weber J. Serotyping HIV type 1 by antibody binding to the V3 Loop: relationship to viral genotype. AIDS Res Hum Retroviruses 1994; 10: 1379-86.
9. Chirmule N, Oyaizu N, Kalyanaraman V, Pahwa S. Inhibition of normal B-cell function by human immunodeficiency virus envelope glycoprotein, gp120. Blood 1992; 79: 1245-54.
10. Deeks S, Schweighardt B, Wrin T, et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 2006; 80: 6155-64.
11. Euler Z, van Gils M, Bunnik E, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 2010; 201: 1045-53.
12. Gilbert P, Peterson M, Follmann D, et al. Correlation between immunologic responses to a recombinant clycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine Trial. J Infect Dis 2005; 191: 666-77.
13. Grant R, Kuritzkes D, Johnson V, et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003; 41: 1586-93.
14. Gray E, Moore P, Choge I, et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007; 81: 6187-96.
15. Humbert M, Dietrich U. The role of neutralizing antibodies in HIV infection. AIDS Rev 2006; 8: 51-9.
16. International AIDS Vaccine Initiative (IAVI). Database of vaccine candidates in clinical trials. New York: IAVI, 2012. [Cited 2012 Aug 3]. Available from: URL: http://www.iavireport.org/ TrialsDatabase/Pages/Results.aspx?searchid=4f4cdd96-f723-4679-8e27-4ad68b8ea5ed
17. Kelly H, Urbanski M, Burda S, et al. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals. Hum Antibodies 2005; 14: 89-99.
18. Kubota-Koketsu R, Mizuta H, Oshita M, et al. Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun 2009; 387: 180-5.
19. Kuritzkes D, Grant R, Feorino P, et al. Performance characteristics of the TRUGENE HIV-1 genotyping kit and the opengene DNA sequencing system. J Clin Microbiol 2003; 41: 1594-9.
20. Lekkerkerker A, Ludwig I, van Vliet S, van Kooyk Y, Geijtenbeek T. Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. Virology 2004; 329: 465-76.
21. Li Y, Migueles S, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13: 1032-4.
22. McLinden R, Paris R, Polonis V, et al. Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS 2012; 26: 1-9.
23. Mikell I, Sather D, Kalams S, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7: e1001251.
24. Moir S, Fauci A. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235-45.
25. Moir S, Malaspina A, Ogwaro K, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A 2001; 98: 10362-7.
26. Moir S, Ogwaro K, Malaspina A, et al. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci USA 2003; 100: 6057-62.
27. Osmanov S, Pattou C, Walker N, Schwardlaender B, Esparza J, WHO-UNAIDS Network for HIV Isolation and Characterization. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29: 184-90.
28. Parren P, Marx P, Hessell A, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75: 8340-7.
29. Piantadosi A, Panteleeff D, Blish C, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 2009; 83: 10269-74.
30. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194: 1661-71.
31. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-20.
32. Richman D, Wrin T, Little S, Petropoulos C. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-9.
33. Rodriguez S, Sarr A, MacNeil A, et al. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)-and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J Virol 2007; 81: 5331-8.
34. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104: 6776-81.
35. Sajadi M, Guan Y, DeVico A, et al. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 2011; 57: 9-15.
36. Setthapramote C, Sasaki T, Puiprom O, et al. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection. Biochem Biophys Res Commun 2012; 423: 867-72.
37. Stiegler G, Kunert R, Purtscher M, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17: 1757-65.
38. Subbramanian R, Xu J, Toma E, et al. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and inhibiting antibodies in AIDS patients. J Clin Microbiol 2002; 40: 2141-6.
39. Taylor B, Sobieszczyk M, McCutchan F, Hammer S. The challenge of HIV-1 subtype diversity. N Engl J Med 2008; 358: 1590-602.
40. The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191: 654-65.
41. Trkola A, Purtscher M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70: 1100-8.
42. Utachee P, Jinnopat P, Isarangkura-na-ayuthaya P, et al. Genotypic characterization of CRF01_AE env genes derived from human immunodeficiency virus type 1-infected patients residing in central Thailand. AIDS Res Hum Retroviruses 2009a; 25: 229-36.
43. Utachee P, Jinnopat P, Isarangkura-na-ayuthaya P, et al. Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand. Microbes Infect 2009b; 11: 334-43.
44. Utachee P, Nakamura S, Isarangkura-na-ayuthaya P, et al. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. J Virol 2010; 84: 4311-20.
45. van Montfort T, Nabatov A, Geijtenbeek T, Pollakis G, Paxton W. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. J Immunol 2007; 178: 3177-85.
46. Walker L, Phogat S, Chan-Hui P, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326: 285-9.
47. Wu X, Yang Z, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329: 856-61.
48. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1990; 280: 1884-8.